Bortero 2mg Injection

About

Bortezomib, the active ingredient in Bortero 2mg Injection, is a potent proteasome inhibitor used in the treatment of certain hematologic malignancies. It works by reversibly inhibiting the 26S proteasome, a multi-catalytic proteinase complex responsible for degrading ubiquitinated proteins. This inhibition disrupts cellular homeostasis, leading to an accumulation of misfolded proteins, activation of pro-apoptotic pathways, and ultimately, programmed cell death in cancer cells. Its targeted mechanism makes it effective against rapidly proliferating cells while sparing healthy cells to a greater extent than traditional chemotherapy. It is particularly crucial in managing multiple myeloma and mantle cell lymphoma, often used in both newly diagnosed and relapsed/refractory settings, either as a monotherapy or in combination with other agents.

Uses

• Treatment of multiple myeloma.
• Treatment of mantle cell lymphoma.
• Used in relapsed and refractory multiple myeloma.
• Part of combination therapy for newly diagnosed multiple myeloma.

Directions For Use

Administered intravenously or subcutaneously by a qualified healthcare professional. The dosage and treatment schedule are determined by the physician based on the patient's specific condition and response.

Benefits

• Targets cancer cells through proteasome inhibition.
• Induces apoptosis in malignant cells effectively.
• Proven efficacy in relapsed/refractory cases.
• Contributes to improved progression-free survival.
• Versatile for use in various combination regimens.
• Offers a precise, targeted approach to cancer therapy.

Side Effects

• Peripheral neuropathy
• Thrombocytopenia
• Neutropenia
• Anemia
• Fatigue
• Nausea
• Diarrhea
• Constipation
• Vomiting
• Fever
• Rash
• Hypotension

Safety Measures

• Alcohol - Alcohol consumption should be approached with caution as it may exacerbate certain side effects or increase liver strain.
• Pregnancy - Bortero is generally contraindicated during pregnancy due to potential fetal harm; effective contraception is advised for patients of childbearing potential.
• Breastfeeding - Breastfeeding is not recommended during treatment with Bortero as the drug may be excreted into breast milk, posing risks to the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary based on liver function tests.
• Kidney - Administer with caution in patients with renal impairment; dose modifications may be required, though severe renal impairment typically does not necessitate significant changes.
• Lung - Monitor for signs of pulmonary toxicity; use with caution in patients with pre-existing lung conditions or risk factors for pulmonary complications.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.